abstract |
The present invention contemplates therapeutic compositions containing a D30 homolog capable of binding to the Mac-1 receptor D30 binding site and inhibiting fibrinogen binding to the Mac-1 receptor via the D30 binding site, Methods of inhibiting Mac-1 receptor binding to any Mac-1 ligand and methods of inhibiting Mac-1 receptor mediated inflammation within a patient by administering a D30 homolog are also contemplated, |